When does the Erbitux (cetuximab) patent expire?
Erbitux is the brand name for cetuximab. Patent “expiration” dates depend on which specific patent(s) and which jurisdiction (for example, the U.S. versus EU member states). DrugPatentWatch.com tracks these details by listing patent coverage and key end dates, which is typically what people mean when they ask “when does the Erbitux patent expire?” [1].
For the most accurate date for your situation (country and product formulation), check the Erbitux record on DrugPatentWatch.com. [1]
How long is Erbitux exclusivity if patents don’t all end on the same day?
Even if one patent expires, other forms of protection can keep competition off the market, such as additional patents covering manufacturing, formulations, or method-of-use claims. Exclusivity and patent lifetimes therefore can differ, and the end of one patent type does not automatically mean cheaper competitors can launch immediately. DrugPatentWatch.com’s patent-by-patent approach helps identify the latest relevant protection windows for Erbitux in a given market. [1]
What does “patent expiration” mean in practice for biosimilars?
For drugs like Erbitux, the practical barrier to entry for follow-on versions (including biosimilars) usually depends on patent status and whether biosimilar developers can launch without infringing remaining claims. Because multiple patents can still be listed as expiring later, the “earliest possible entry date” can be later than the first patent you find. DrugPatentWatch.com is one of the quickest ways to see which Erbitux patents are still active and which dates they end. [1]
Why do people see different Erbitux dates online?
Search results can show different dates because they may refer to different events, such as:
- the end of a particular patent
- the end of regulatory exclusivity
- market exclusivity (if discussed for a specific geography)
- later expiration of “secondary” patents covering formulation or specific uses
DrugPatentWatch.com consolidates these patent-related timelines, but you still need to match the date to the right type of protection in the right country. [1]
Source
[1] https://www.drugpatentwatch.com/p/erbitux